Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
AstraZeneca
Dow
Baxter

Last Updated: May 20, 2022

ZIOPTAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Zioptan, and what generic alternatives are available?

Zioptan is a drug marketed by Akorn and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in thirty-one countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tafluprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zioptan

A generic version of ZIOPTAN was approved as tafluprost by MICRO LABS on August 19th, 2019.

  Sign up for a Free Trial

Paragraph IV (Patent) Challenges for ZIOPTAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZIOPTAN Ophthalmic Solution tafluprost 0.0015% 202514 2 2016-02-10

US Patents and Regulatory Information for ZIOPTAN

ZIOPTAN is protected by three US patents.

Patents protecting ZIOPTAN

Method and composition for treating ocular hypertension and glaucoma
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Difluoroprostaglandin derivatives and their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Method and composition for treating ocular hypertension and glaucoma
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Akorn ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Akorn ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZIOPTAN

When does loss-of-exclusivity occur for ZIOPTAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1937
Estimated Expiration: See Plans and Pricing

Australia

Patent: 09252210
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0913109
Estimated Expiration: See Plans and Pricing

Canada

Patent: 24194
Estimated Expiration: See Plans and Pricing

Patent: 65185
Estimated Expiration: See Plans and Pricing

China

Patent: 2083413
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0140979
Estimated Expiration: See Plans and Pricing

Patent: 0170769
Estimated Expiration: See Plans and Pricing

Patent: 0200998
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 15565
Estimated Expiration: See Plans and Pricing

Patent: 20351
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 06977
Estimated Expiration: See Plans and Pricing

Patent: 72249
Estimated Expiration: See Plans and Pricing

Patent: 05334
Estimated Expiration: See Plans and Pricing

Patent: 14877
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 3661
Estimated Expiration: See Plans and Pricing

Patent: 1071413
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 27638
Estimated Expiration: See Plans and Pricing

Patent: 06977
Estimated Expiration: See Plans and Pricing

Patent: 72249
Estimated Expiration: See Plans and Pricing

Patent: 05334
Estimated Expiration: See Plans and Pricing

Patent: 14877
Estimated Expiration: See Plans and Pricing

Georgia, Republic of

Patent: 0156220
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 33103
Estimated Expiration: See Plans and Pricing

Patent: 49923
Estimated Expiration: See Plans and Pricing

Japan

Patent: 48317
Estimated Expiration: See Plans and Pricing

Patent: 56868
Estimated Expiration: See Plans and Pricing

Patent: 49992
Estimated Expiration: See Plans and Pricing

Patent: 89789
Estimated Expiration: See Plans and Pricing

Patent: 11521943
Estimated Expiration: See Plans and Pricing

Patent: 14133765
Estimated Expiration: See Plans and Pricing

Patent: 16065095
Estimated Expiration: See Plans and Pricing

Patent: 17178957
Estimated Expiration: See Plans and Pricing

Patent: 18154656
Estimated Expiration: See Plans and Pricing

Patent: 20073574
Estimated Expiration: See Plans and Pricing

Patent: 21120412
Estimated Expiration: See Plans and Pricing

Jordan

Patent: 39
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 72249
Estimated Expiration: See Plans and Pricing

Patent: 05334
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 9463
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 10012987
Estimated Expiration: See Plans and Pricing

Poland

Patent: 06977
Estimated Expiration: See Plans and Pricing

Patent: 72249
Estimated Expiration: See Plans and Pricing

Patent: 05334
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 06977
Estimated Expiration: See Plans and Pricing

Patent: 72249
Estimated Expiration: See Plans and Pricing

Patent: 05334
Estimated Expiration: See Plans and Pricing

Patent: 14877
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 1628
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 06977
Estimated Expiration: See Plans and Pricing

Patent: 72249
Estimated Expiration: See Plans and Pricing

Patent: 05334
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1650006
Estimated Expiration: See Plans and Pricing

Patent: 1820816
Estimated Expiration: See Plans and Pricing

Patent: 1988642
Estimated Expiration: See Plans and Pricing

Patent: 2114401
Estimated Expiration: See Plans and Pricing

Patent: 2246598
Estimated Expiration: See Plans and Pricing

Patent: 110011707
Estimated Expiration: See Plans and Pricing

Patent: 160102319
Estimated Expiration: See Plans and Pricing

Patent: 180008905
Estimated Expiration: See Plans and Pricing

Patent: 190067272
Estimated Expiration: See Plans and Pricing

Patent: 200057801
Estimated Expiration: See Plans and Pricing

Spain

Patent: 95316
Estimated Expiration: See Plans and Pricing

Patent: 27837
Estimated Expiration: See Plans and Pricing

Patent: 08050
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 32202
Estimated Expiration: See Plans and Pricing

Patent: 1000104
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 2257
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZIOPTAN around the world.

Country Patent Number Title Estimated Expiration
Spain 2808050 See Plans and Pricing
Norway 976085 See Plans and Pricing
Japan 2017178957 高眼圧症及び緑内障を治療するための方法及び組成物 (METHODS AND COMPOSITIONS FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA) See Plans and Pricing
Croatia P20140979 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZIOPTAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0850926 91943 Luxembourg See Plans and Pricing 91943, EXPIRES: 20221222
0850926 339 Finland See Plans and Pricing
0850926 SPC013/2011 Ireland See Plans and Pricing SPC013/2011: 20110808, EXPIRES: 20221221
0850926 300407 Netherlands See Plans and Pricing 300407, 20171222, EXPIRES: 20221221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKesson
Mallinckrodt
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.